In addition, the rate of clinical progression in AD patients is tightly associated with the properties of soluble oligomeric HMW tau [17], as well as analogous differences in fibrillar tau [32], raising the question of how fibrillar and oligomeric tau compare with each other. This evidence concerns the gene MAPT and Alzheimer disease.